Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03372395
Other study ID # 3642
Secondary ID
Status Completed
Phase Phase 2
First received November 14, 2017
Last updated December 8, 2017
Start date February 2015
Est. completion date April 2016

Study information

Verified date December 2017
Source University of Roma La Sapienza
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Over recent years, a growing interest has developed in microbiota and in the concept of maintaining a special balance between Lactobacillus and other bacteria species in order to promote women's well-being. The aim of the study was to confirm that vaginal Lactobacilli long-lasting implementation in women with HPVinfections and concomitant bacterial vaginosis or vaginitis might be able to help in solving the viral infection, by re-establishing the original eubiosis.


Description:

A total of 117 women affected by bacterial vaginosis or vaginitis with concomitant HPV infections were enrolled at Department of Gynecological Obstetrics and Urological Sciences, La Sapienza University, Rome, Italy between February 2015 and March 2016. Women were randomized in two groups, standard treatment (metronidazole 500 mg twice a day for 7 days or fluconazole 150 mg orally once a day for 2 consecutive days) plus short-term (3 months) vaginal Lactobacillus implementation (group 1, short probiotics treatment protocol group, n=60) versus the same standard treatment plus long-lasting (6 months) vaginal Lactobacillus rhamnosus BMX 54 administration (group 2, treatment group, n=57).


Recruitment information / eligibility

Status Completed
Enrollment 117
Est. completion date April 2016
Est. primary completion date March 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- age>18 years

- documented BV or yeast vaginitis associated with HPV-infection documented as PAP-smear abnormalities (ASCUS, L-SIL or H-SIL histologically demonstrated as CIN1) and/or positive for HPV-DNA

Exclusion Criteria:

- pregnancy or breastfeeding

- previous abnormal PAP-smear

- CIN2-3

- concomitant malignancies

- immunological diseases

- severe comorbidities

- prolonged corticosteroid treatment.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Lactobacillus rhamnosus BMX 54
Given once a day for 10 days, once every 3 days for 20 days and then once every 5 days for other 2 months in all patients (probiotics implementation for 3 months comprehensively).

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University of Roma La Sapienza

References & Publications (1)

Recine N, Palma E, Domenici L, Giorgini M, Imperiale L, Sassu C, Musella A, Marchetti C, Muzii L, Benedetti Panici P. Restoring vaginal microbiota: biological control of bacterial vaginosis. A prospective case-control study using Lactobacillus rhamnosus BMX 54 as adjuvant treatment against bacterial vaginosis. Arch Gynecol Obstet. 2016 Jan;293(1):101-7. doi: 10.1007/s00404-015-3810-2. Epub 2015 Jul 5. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of a possible role of probiotics in vaginal infections resolution Changes in clinical responses (absence of typical symptoms associated with vaginal infections) 9 months
Secondary Treatment-related adverse events record Assessed by CTCAE v4.0 9 months
See also
  Status Clinical Trial Phase
Completed NCT00324246 - Feasibility Study of the NEW NORMA-SENSE Phase 3
Recruiting NCT05021315 - Vaginal Cleaning Using Povidone Iodine Before CS to Reduce Postoperative Wound Infection Phase 3
Not yet recruiting NCT05997160 - Research on Vaginal Microbiota Evaluation Unified Standards Based on Gram Staining
Recruiting NCT05557318 - Using Micro Electro Mechanical Systems to Detect the Air of Vaginal Discharge N/A
Completed NCT05044156 - Investigation of the Relationship Between Salivary Histatine-5 Level and Vaginal Candidiasis in Women
Completed NCT00694928 - Vaginal Infection Study 2 Phase 3
Not yet recruiting NCT05590195 - Effect of PreforPro® on Urinary and Vaginal Health Phase 3
Completed NCT03898726 - Laparoscopic Versus Transvaginal Cuff Closure N/A
Withdrawn NCT01542606 - Performance Proof of Product Developed to Detect Abnormal Vaginal pH N/A
Not yet recruiting NCT05806879 - Impact of Maternity Napkins on the Incidence of Vaginal Infections in the Post-partum Period N/A
Completed NCT02308033 - Multi-Center Study of New Medications to Treat Vaginal Infections Phase 3
Completed NCT02308007 - Multi-Center Study of New Medications to Treat Vaginal Infections Phase 3
Completed NCT02308046 - Multi-Center Study of New Medications to Treat Vaginal Infections Phase 3
Completed NCT01599416 - Influence of U-relax on Vaginal Health Promotion and HPV DNA Test Change From Positive to Negative N/A
Recruiting NCT04719754 - Epidemiology of Abnormal Vaginal Discharge During Pregnancy
Completed NCT03261804 - Relation Between Internal Vaginal Douching and Vaginal Infections in Intrauterine Contraceptive Device Users
Completed NCT03008421 - Oral Probiotics to Reduce Vaginal Group B Streptococcal Colonization in Late Pregnancy N/A
Terminated NCT05788991 - Comparison of Dequalinium Chloride (Fluomizin) vs Oral Metronidazole for the Treatment of Bacterial Vaginosis Phase 4
Completed NCT01843166 - Vaginal Estrogen With Pessary Treatment N/A
Not yet recruiting NCT03532464 - Azithromycin Compared With Doxycycline for Treating Anorectal Chlamydia Trachomatis Infection Concomitant to a Vaginal Infection Phase 4